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ABSTRACT
Objective: Develop and implement a prescription opioid registry in 10 diverse health systems across the US
and describe trends in prescribed opioids between 2012 and 2018.
Materials and Methods: Using electronic health record and claims data, we identified patients who had an outpatient fill for any prescription opioid, and/or an opioid use disorder diagnosis, between January 1, 2012 and December
31, 2018. The registry contains distributed files of prescription opioids, benzodiazepines and other select medications,
opioid antagonists, clinical diagnoses, procedures, health services utilization, and health plan membership. Rates of
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LAY SUMMARY
Prescription opioid use has played a large role in the opioid crisis over the last 2 decades. This article describes the development and implementation of a population-based prescription opioid registry using electronic health record and claims data
from 10 diverse health systems in the United States. We also conduct descriptive analyses of opioid use trends over the
study period of January 1, 2012–December 31, 2018. Patients who filled a prescription for an opioid, and/or had an opioid
use disorder diagnosis in the study period are included in the registry. The registry contains several data domains: patient
demographics, medications, including prescription opioids and benzodiazepines, clinical diagnoses, health procedures,
health services utilization, health plan membership, and mortality. The registry includes 6 249 710 patients and over 40 million outpatient opioid fills. Descriptive analyses showed large reductions in overall opioid use per member among the combined health systems over the study period. The registry is a large, comprehensive data resource with a flexible data structure that can be leveraged in future studies to answer a broad range of critical public health questions relating to
prescription opioid use. The design may be useful for other research teams developing similar data resources.

INTRODUCTION
The United States continues to face an opioid crisis,1 and while prescription opioids do not drive recent steep increases in mortality,2
they cause a considerable number of overdose deaths.1,3,4 Although
opioid prescribing has decreased nationally since 2012,5,6 the morphine equivalents prescribed per person is 3 times the 1999 level.7 In
2020, 9.3 million people older than 12 years misused prescription
pain medications in the past year, making it the second most commonly misused drug after cannabis.8 In 2020, 2.3 million people
had a pain medication use disorder and 2.7 million people had an
opioid use disorder (OUD).9 Prescription opioid misuse is also a risk
factor for heroin use.10
In response to the crisis, national and professional guidelines
have outlined cautions about prescribing at high levels, to whom to
prescribe, and how to manage long-term opioid treatment.11 Critical
questions remain about the prescribing environment that has
changed quickly as the opioid crisis evolves. Studies that can leverage large population-level data are needed to address research priorities about opioid prescribing limits, opioid dose reductions, and use
of medications for OUD.
Disease registries and robust electronic health record (EHR) data
are cited as valuable resources to address critical research questions
with high efficiency.12 These data sources can be leveraged to increase our understanding of the impact of changing opioid use
trends, and inform future research. Registries have been developed
for various disease conditions, including chronic medical conditions,13–15 and alcohol problems,16 and the research team’s prior
work on a prescription opioid registry in a single health system.17
To our knowledge, no study has established an EHR-based prescription opioid registry across multiple, diverse health systems with har-

monized data and the ability to address current questions of
prescription opioid use and OUD.
The goal of the overall project was to use EHR and insurance
claims data to develop a prescription opioid registry across 10 diverse health systems with the ability to address important public
health questions relating to opioid use, including questions of trends
in use over time, reductions in opioid use and adverse events, opioid
prescribing limits, and optimal length of buprenorphine treatment
for OUD. It draws on our, and others, previous opioid research
methodology and assumes that opioid fills represent use, a typical
approach in studies based on pharmacy data.18–20
The objective of this article is to describe the development and
implementation of the registry, the population it contains, and provide descriptive information on rates of opioid use from 2012 to
2018. The description of our methodological approach may be useful to other research teams and health systems in their efforts to
study prescription opioid use and related problems.

MATERIALS AND METHODS
Setting
The opioid registry was developed in 10 health systems across several states: Baylor Scott and White, Texas; Essentia Health System,
Minnesota, North Dakota, Wisconsin; Geisinger Health Systems,
Pennsylvania; Henry Ford Health System (HFHS), Michigan; Kaiser
Permanent Colorado; Kaiser Permanente Mid-Atlantic States, Maryland, Virginia, Washington DC; Kaiser Permanente Northern California (KPNC); Kaiser Permanente Northwest, Oregon; Kaiser
Permanente Southern California; and Meyers Primary Care Institute/Fallon Health, Massachusetts (Table 1).
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outpatient opioid fills over the study period, standardized to health system demographic distributions, are described
by age, gender, and race/ethnicity among members without cancer.
Results: The registry includes 6 249 710 patients and over 40 million outpatient opioid fills. For the combined
registry population, opioid fills declined from a high of 0.718 per member-year in 2013 to 0.478 in 2018, and
morphine milligram equivalents (MMEs) per fill declined from 985 MMEs per fill in 2012 to 758 MMEs in 2018.
MMEs per member declined from 692 MMEs per member in 2012 to 362 MMEs per member in 2018.
Conclusion: This study established a population-based opioid registry across 10 diverse health systems that
can be used to address questions related to opioid use. Initial analyses showed large reductions in overall opioid use per member among the combined health systems. The registry will be used in future studies to answer
a broad range of other critical public health issues relating to prescription opioid use.
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Table 1. Description of opioid registry sites
Site
Baylor Scott and White
Essentia Health System

Texas
Minnesota, North Dakota,
Wisconsin
Pennsylvania
Michigan
Colorado

Medication sourcea

Enrollmentb

Tumor registry

Fills
Orders

Membership-based
Utilization-based

None
Through December 31, 2018

Orders/fillsc
Orders
Fills

Membership and utilization-based
Utilization-based
Membership-based

Through December 31, 2018
Through December 31, 2018
Through December 31, 2018

Maryland, Virginia, Washington DC
Oregon

Fills

Membership-based

Through December 14, 2018

Fills

Membership-based

Through December 31, 2018

Northern California

Fills

Membership-based

Through December 31, 2017

Southern California

Fills

Membership-based

Through December 31, 2018e

Massachusetts

Fills

Membership-based

Through December 15, 2016

a

The primary source for prescription medications is fills. Some sites capture only medication orders for some or all their registry patients.
“Enrollment” refers to periods of time when the health system expects to have complete data for the patient. For most health systems, periods of enrollment
are based on periods of paid membership. Other health systems serve patients who are not paid members and a utilization algorithm is used to determine periods
of “proxy” enrollment. Finally, some sites serve a combination of these types of patients.
c
For nonmember patients, orders and utilization-based enrollment algorithms are used; for member patients, fills and membership-based enrollment periods
are used.
d
Henry Ford Health System opioid registry includes data from January 1, 2014 to December 31, 2018. All other sites include data from January 1, 2012 to December 31, 2018.
e
Tumor data for registry patients are included in the KPSC opioid registry. However, tumor data were not provided for other health plan members and therefore total denominator noncancer person time was not be determined.
b

The health systems are diverse, representing different geographic
regions, patient populations, and delivery systems including primarily integrated delivery systems and health systems with mixed-model
delivery systems (HFHS, Geisinger). The health systems are sites of
the Health Systems Node of the National Drug Abuse Treatment
Clinical Trials Network (CTN), which funded the project, and thus
have established collaborative relationships that facilitated the development of the registry. Each health system has a Site Principal Investigator (PI) for the registry—this local investigator is an
embedded researcher at their health system with expertise in local
data structures and clinical environments.

Protocol
Protocol development was guided by prior work,17 as well as other
disease registries13–15 and Agency for Healthcare Research and
Quality guidelines for research registries.21 KPNC, the lead site, collaborated with the local research team at each health system as well
as consultants in the addiction field from the CTN to develop the
approach. The protocol was approved by the National Drug Abuse
Treatment CTN, and the KPNC Institutional Review Board (IRB)
was the IRB of record for this multisite study.

Data sources
The primary data source was the Health Care Systems Research
Network (HCSRN) Virtual Data Warehouse (VDW), a distributed
data model which combines and harmonizes EHR, insurance claims,
and mortality data across the participating health systems.22 Programmers at each health system transform EHR and claim data elements from local data systems to a VDW standardized set of

variable definitions, names, and codes. The VDW has been established for over 20 years, with rigorous harmonizing and quality assurance protocols. The common data structure allows for an
efficient approach where health systems can exchange programming
code developed at 1 health system and minimally adapt that code at
other health systems to extract and analyze data.

Registry structure
The registry has a distributed data structure similar to the VDW,
with a set of relational files that each represents a main content area
(eg, opioid fills) (Figure 1). Records associated with the same patient
are linked using a unique Study ID. The registry currently includes
18 patient-related files, 1 census-related file, 2 health plan persontime denominator files, and 5 lookup tables (Table 2). Patientrelated files contain records linked to a specific individual (eg, opioid fills or diagnoses). The census-related file contains census information for each census tract in the health system’s service area. The
person-time denominator files include person-time of the system’s
underlying service population summarized by calendar month and
stratified by gender, age, race/ethnicity, and cancer status. Lookup
tables allow for elements like drug codes to be mapped to descriptions and strength. Files cover the following data domains: membership, mortality, provider-assigned diagnoses, OUD diagnoses,
pharmacy fills/orders for opioids, benzodiazepines, gabapentin, “Zdrugs” (eg, zolpidem), antidepressants, procedures, providers, cancer diagnoses, and health care utilization. Files also contain created
variables to support analyses (eg, person-time denominators). With
a distributed structure, each health system maintains its own local
version of the registry.
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Geisinger Health Systems
Henry Ford Health Systemd
Kaiser Permanente Colorado
Kaiser Permanente Mid-Atlantic
Kaiser Permanente Northwest
Kaiser Permanente Northern California
Kaiser Permanente Southern California
Meyers Primary Care Institute/Fallon Health

Geographic area covered
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Figure 1. Opioid registry entity relationship diagram with selected variables shown.

Registry patients/inclusion criteria
Patients were included if, between January 1, 2012 and December 31,
2018, they had at least 1 outpatient opioid fill (or order at 3 of the
mixed-model health systems) and/or an OUD diagnosis, and were 
age 18 at the time of at least 1 opioid fill or OUD diagnoses. The regis-

try’s focus is on prescribed opioids (and includes all forms of buprenorphine), but patients with OUD were included to permit future
studies of this patient group regardless of whether they had an opioid
prescription. We defined the patient’s registry entry date as the earliest
of their first opioid fill or OUD diagnosis during the registry period.
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Table 2. Description of opioid registry files
File typea

Benzodiazepine drug list
Benzodiazepine fills/orders
Cancer diagnoses
Cause of death
Census demographics
Census locations
Coverage
Death
Diagnosis
Enrollment
Gabapentin/Z-drugs/Antidepressant drug list
Gabapentin/Z-drugs/Antidepressant fills/orders
Geocoded addresses for patients
Member-time denominators (2 files)

Lookup
Patient
Patient
Patient
Census
Patient
Patient
Patient
Patient
Patient
Lookup
Patient
Patient
Member-time

Opioid antagonist drug list
Opioid antagonist fills/orders
Opioid drug list
Opioid fills/orders
Opioid use disorder diagnoses
Opioid use disorder diagnosis codes
Patiente
Procedures
Study ID crosswalk
Tumor
Utilization

Lookup
Patient
Lookup
Patient
Patient
Lookup
Patient
Patient
Patient
Patient
Patient

File description and notes
List of benzodiazepine NDCs/DRUG_IDs
Benzodiazepine fills/ordersb
Provider documented cancer diagnosesc
Causes of death
Census data for all patient census tracts
Census tract for each patient address during opioid registry period
Medicare/Medicaid status of each subject in each month
Known deaths and date of death for patients
Provider documented diagnoses
Periods of enrollment in site health system
List of gabapentin, Z-drugs, antidepressant NDCs/DRUG_IDs
Gabapentin, Z-drugs, antidepressant fills/ordersb
Census block group of patient based on addresses
Member-time of the underlying population summarized by calendar
month stratified by gender, age, race, and cancer status defined
using (1) tumor or (2) cancer diagnosis datad
List of opioid antagonist NDCs/DRUG_IDs
Opioid antagonist fills/ordersb
List of opioid NDCs/DRUG_IDs
Opioid fills/ordersb
Opioid use disorder diagnoses
List of ICD9/ICD10 codes for opioid use disorder
One record with every patient, including demographic and other data
Procedures
Crosswalk between patient ID used by site VDW and Study ID
Tumorsf
Health services utilization (eg, visits, hospitalizations)

a

“Patient” files include individual patient-level data (in the file’s domain) for all persons from their observation start date until December 31, 2018. “Census”
file includes census-related information for all census tracts. “Lookup” files include registry-related code sets. “Member-time” files include summarized persontime “at-risk,” used as denominators. For most health systems member-time is based on periods of paid membership for all adult members of the health plan during the registry period. Other systems serve persons who are not members of their system and a utilization algorithm is used to determine periods of “proxy”
membership. Finally, some sites serve a combination of these persons and use both membership- and utilization-based proxy membership to estimate membertime.
b
Records represent outpatient medication fills at those sites with complete (or near complete) medication fill data for their member patients. Records represent
prescriber orders at those sites with incomplete or no fill data.
c
Cancer diagnoses. The primary use of this file is to censor patients at first cancer diagnosis within registry period or to identify if a person may be using opioids
due to cancer pain. This file was used as a substitute for the Tumor file for those sites without a tumor file, and/or in combination with the Tumor file, and/or for
sensitivity analyses.
d
(1) Member months had a status of “cancer” if they occurred after the member’s first tumor date during the registry period. (2) Member months had a status
of “cancer” if they occurred after the member’s first cancer diagnosis during the registry period. Member time refers to the underlying population “at risk” for receiving opioid prescriptions. It includes persons who had opioid fills during the registry period as well as persons who did not have any opioid fills.
e
Registry patients are all adults who had either an outpatient opioid fill/order and/or an opioid use disorder diagnosis between January 1, 2012 and December
31, 2018.
f
Tumor records indicate all new tumors identified during the registry period. Some health systems do not have a cancer registry or tumor file. The primary use
of this file is to censor patients at date of first tumor.

Registry files and data elements
We describe here the opioid fills, OUD, patient, and memberdenominator files included in the registry since they are instrumental
for entry into the registry and initial analyses of trends in opioid use.
Each health system maintains their own set of files, containing data
during the registry period (January 1, 2012–December 31, 2018)
with the exception of one system which begins in 2014.
The opioid fills file contains a record for each outpatient opioid
fill (or, at 3 sites, each order) during the registry period. For those
sites using orders, all opioid orders—whether filled or not—are included. We excluded antitussives, anesthetics, antihistamines, antidiarrheals, and injectables. We include opioid formulations
(including buprenorphine) used in the research team’s prior research,17–20 cross-referenced with the Centers for Disease Control
and Prevention’s (CDC) “Opioid NDC and Oral MME Conversion

File”.23 Each record includes the date of the fill, the opioid’s National Drug Code, a prescribing provider identifier, the amount dispensed, the day’s supply and (when linked to the opioid lookup
table), the type and form of opioid (eg, “hydrocodone” and
“tablets”), strength per unit of the active opioid ingredient, and
morphine milligram equivalent (MME) per unit. We calculated
MMEs using Center for Medicare and Medicaid strength and conversion factors (Supplementary Appendix 1).23
The OUD diagnosis file contains a record for each OUD diagnosis during the registry period. The patient file contains one record
for each person in either the opioid use file or the OUD diagnosis
file, and includes demographic information and the patient’s registry
entry date. The patient file also includes an “observation start date”
for each person that allows for a “look-back” period which is the
latest of: (1) 1 year prior to the registry entry date; (2) the patient’s
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Implementation and maintenance of the opioid registry
The opioid registry was implemented between September 2018 and
May 2021, with a lead data scientist at KPNC and programmers at
each participating health system. The overall registry team of site
PIs, programmers, analysts, project managers, and consultants met
biweekly to develop the data algorithms and data analytic strategies,
troubleshoot data quality issues, and discuss initial findings of research questions. Each site had a site investigator with local knowledge to help put data, trends, and data anomalies into local context;
these individuals also typically had content expertise in opioids, behavioral health, pharmacoepidemiology, addiction medicine, and
biostatistics. In addition to related expertise among the site PIs, expertise from pain management and addiction medicine clinicians at
each site was sought as needed.
The parent programming code was developed at the lead health
system (KPNC) and then uploaded to a secure website for local programmers to access and implement at their health systems. Quality
assurance procedures were iterative between each health system and
KPNC. For each registry file, we generated a report with frequency
counts and/or descriptive statistics that were reviewed by KPNC and
the local health system for missing data and data anomalies. Five additional audit reports were run at each site after all files were created, which were reviewed by KPNC and the local health system.
When possible, electronic chart review was conducted selectively to
understand extreme outliers or missing data. All data anomalies
were corrected as necessary. All code were written in SAS. Data elements were kept as granular as possible, and data cleaning minimized, to allow future studies flexibility regarding the format and
structure of the data adapted to their own specific research questions. An overall data dictionary was developed. Although the data
are maintained locally, bidirectional data sharing agreements were
developed with each health system that allowed for qualityassurance activities, as well as approval for initial trend analyses.

Trends in opioid use from 2012 to 2018
Opioid prescribing guidelines and initiatives have focused primarily
on noncancer patients, given that pain management for cancer
patients has different clinical considerations. To describe trends in
opioid prescribing among the noncancer population, we first

extracted all opioid fills and associated MMEs from the registry opioid fill file, excluding fills after the date of a first malignant or metastatic tumor. Number of opioid fills and associated MMEs were
summarized by calendar month into strata by patient age (at the
time of the fill), gender, and race. Member-time denominators by
calendar month, age, race, and cancer-status were extracted from
the member-time files, and we retained only noncancer membertime strata. (Due to incomplete tumor data, 2 health systems used
all opioid fills and all person-time for these analyses.) We calculated
the opioid fills and total MMEs per member-month in each calendar
month for the entire noncancer membership and by gender, age, and
race groups. These rates measure overall opioids filled in the member population and therefore reflect both the amount of opioids received per patient and overall number of patients receiving opioids.
We used direct standardization to standardize the rates to the gender, age and race/ethnicity distribution of the 2018 noncancer member population for all sites combined. When analyzing trends by
demographic subgroups, the reference group for standardization
was the 2018 population of that subgroup.
In addition, to understand the trends in noncancer use within the
changing prescribing environment, we conducted interrupted time
series (ITS) analyses treating the publication of the 2016 CDC
Guideline for Prescribing Opioids for Chronic Pain as an
“intervention.” The input dataset consisted of 1 record per month
from January 2012 to December 2018. The dependent variable in
the ordinary-least-squares model was the MMEs filled per membermonth, standardized to the 2018 distribution of opioid registry
members. Because preliminary inspection of the trend in MMEs per
member-month indicated a possible change in slope beginning in
2014, we ran a sensitivity analysis using 2014, instead of 2012, as
the starting date. We used SAS software Version 9.3 (SAS Institute
Inc., Cary, NC, USA), and PROC AUTOREG to identify and adjust
for any significant autoregressive terms.

RESULTS
Opioid registry patient characteristics
Across all 10 sites, the opioid registry included 6 249 710 patients,
of whom 56% were women (Table 3), 35% were 18 to <40 years of
age, 44% were 40 to <65, 16% were 65 to <80, and 5% were 80
years of age. Registry patients were diverse in terms of race/ethnicity, with 7% being Asian, 10% Black, 21% Hispanic, 9% other/unknown, and 53% white. In total, the registry captured over 40
million individual outpatient opioid fills.

Trends over time in outpatient opioid fills and MMEs
The number of prescription opioid fills and total MMEs per
member-year declined between 2012 and 2018 (Figure 2). The decline in MMEs per member-year reflects both declines in the number
of fills per member-year and in the MMEs per fill. The number of
opioid fills increased from 0.714 per member-year in 2012 to 0.718
in 2013, and then declined from 0.718 in 2013 to 0.478 in 2018.
MMEs per fill declined from an average of 985 per fill in 2012 to
758 in 2018. As a result, MMEs declined from 692 per memberyear in 2012 to 362 in 2018. By December 2018, MMEs per member month were less than half of what they were in January 2012
(Figure 2). MMEs per member-month declined among both men
and women, although declines were greater for women. By December 2018 the MMEs per member-month were approximately the
same for both genders (Figure 3). Similar declines were seen in all
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18th birthday; or (3) January 1, 2012. All other patient-related files
(eg, service utilization, diagnoses, procedures) only include records
for events occurring between the patient’s observation start date and
December 31, 2018.
The registry contains a summary member-time file with a record
for every calendar month of the registry period with the number of
members covered by the health plan during that month. These
monthly denominator records are stratified by gender, age, race,
and cancer-status, and are used to calculate rates of prescription
opioid fills and MMEs in the underlying member-population served
by the registry health systems. For health systems that offer health
insurance, we defined the monthly denominators based on periods
of paid enrollment (“membership”) during the registry period; these
patients have strong financial incentives to use that health care system. Two health systems used a utilization algorithm to determine
denominator person-time because they regularly provide health
care to persons for whom they do not provide insurance.24,25 One
site used paid enrollment to determine person-time for members
and the utilization-based proxy for all other persons receiving care
at their site.

JAMIA Open, 2022, Vol. 5, No. 2

JAMIA Open, 2022, Vol. 5, No. 2

7

Table 3. Distribution of patients in opioid registry by demographics
by site (n ¼ 6 249 710)
Characteristic

56.23
43.76
0.01
34.86
43.83
16.14
5.18
7.05
10.30
20.50
1.08
0.37
0.39
0.47
6.67
53.1

a
Persons could be classified as “multiracial” if the primary race source at
the site included multiracial as a category or allowed multiple different races
to be specified.

age (Figure 4) and race/ethnicity groups (Figure 5). In particular, observed differences in MMEs per member-month by race/ethnicity
were substantially less by the end of the study.
The ITS analysis examining the impact of the CDC Guideline using 2012 as the starting year indicated a statistically significant
change in the trend in overall MMEs per member-month, with the
postguideline trend having a steeper decline by 0.11 MMEs per
month than the preguideline trend (Table 4). The ITS also indicated
a downward shift in the postguideline trend of 0.72 MMEs per
month, but this was not statistically significant (CI: 2.03 to 0.59).
In the sensitivity analysis using 2014 as the starting date rather than
2012, we found no statistically significant changes in opioid use following the 2016 Guideline.

DISCUSSION
We developed and implemented an opioid registry representing 10
diverse health systems across the United States with a distributed
data structure that includes patients with any prescription opioid
use and/or OUD diagnosis. The registry contains over 6 million
patients, diverse in terms of age, race, and gender, and over 40 million outpatient opioid prescription fills/orders. During the ongoing
opioid-related public health crisis, this rich data source can be used
to address critical questions of opioid prescribing.
Prescription opioid use declined steadily over the registry time
period, beginning in 2012, measured by number of fills per member,
MMEs per fill, and overall MMEs per member. Prescribers both reduced the number of prescriptions—fills per member-year declined
by 33%— and the morphine-equivalents per fill (by an average of
23%). Combined, this resulted in overall reductions in opioid use
per member-year by 48% over the registry period. These declining
trends are consistent with national, Veteran’s Health Administration
(VA), and community health clinic data,26–28 but at odds with a recent study using a large, national claims database of commercially
insured and Medicare Advantage patients.27 It is unclear why the
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Gender (% of site patients)
Women
Men
Unknown
Age group (%)
18 to <40
40 to <65
65 to <80
80þ
Race/Ethnicity (%)
Asian
Black
Hispanic
Multiraciala
Native American
Other
Pacific Islander
Unknown
White

All sites (%)

contrasting findings, given a similarly insured population, although
it is possible that the registry health systems were more nimble in
changing opioid prescribing.
The decline in prescribing considerably predates the 2016 CDC
Guideline for Prescribing Opioids for Chronic Pain.11 Findings do not
indicate an additional impact of the CDC guidelines, contrary to a
study by Bohnert et al26 using national pharmacy data with 2012 as
the first measurement year, but are consistent with a more recent analysis.29 The measurement year makes a difference—we observed an association with CDC guidelines using 2012 as the initial measurement
year, but not when using 2014 as the starting year, which we selected
after observing that opioid use began a steeper decline in that year.
Physicians may have had concerns about prescribing opioids
prior to 2016, and changed prescribing behavior. In addition, during
the study time period health systems also implemented local prescribing initiatives,28,30 which included reducing high dosages, additional criteria for initial prescriptions, and greater monitoring of
high dose patients. Changes in acute and surgical pain treatment
may also be reflected in decreased outpatient opioid use. Federal
and state policies during the study period likely impacted trends, including: Centers for Medicare and Medicaid Services safety rules for
opioid prescribing31; Food and Drug Administration risk evaluation
and mitigation strategy on opioid prescriber education32; state prescription drug monitoring programs were implemented and integrated with health system EHRs; state limits on prescription
duration, and; pain clinic regulations (eg, certification).
All demographic groups experienced a decline in opioid use, although some more modestly. Declines in use among women were
greater than declines among men, which is important given past research showing older women have higher prevalence of long-term
opioid use and that women are more likely to present with pain and
be prescribed a pain medication.20 Declines were seen in every age
group, although steepest for the older age groups, even among those
over 80 years of age, which may have positive implications for the
risks of adverse events such as falls in the elderly. We also observed
a narrowing of differences in opioid use among race/ethnicity
groups, and in particular for Native American and white patients.
Native Americans had considerably higher use than other race/ethnicity groups at the beginning of the study period and experienced
the steepest decline over time.
Reasons for the convergence among the demographic groups
cannot be determined with these data. Safer opioid prescribing
efforts have focused on the highest dosage patients, which may
translate into the steeper decreases observed here. Women typically
use more health services, which present more opportunity for intervention (eg, tapering),33 and they are also more likely to have coprescribing of benzodiazepines which may trigger greater scrutiny.
Exploring the impact of reduced use in these patient subpopulations
is an important research area, particularly with respect to patient
outcomes such as functional status and pain. Few studies using large
electronic datasets report trends in MMEs over this time period by
age and gender, particularly with a population-based denominator,
and to our knowledge none have done so by race and ethnicity. It
will be important to continue to analyze these trends past 2018.
Observational data can be a key complement to traditional clinical trial and national survey data to address critical questions of the
opioid crisis. Primary data collection is often not feasible given the
considerable time and financial resources needed. Secondary data
sources based on routinely collection health care data such as those
used in the opioid registry, have significant advantages in reaching
similar research goals given their large, diverse patient samples and
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Figure 3. Outpatient morphine milligram equivalents filled per member-month by gender and month, all opioid registry sites combined, 2012–2018.

“real world” settings. The current registry uses EHR data, which
can offer advantages over even some very large claims datasets,
given the ability to access primary electronic data sources for data
quality assessment or for focused auxiliary analyses, and their relatively greater depth compared with deidentified claims data.
Several elements facilitated the implementation of the registry, including a team with extensive expertise in analyzing EHR data. The
team had experience running distributed code, conducting quality-assurance on EHR data, and using a common data model based on experience as members of the HSCRN. A critical piece is the involvement
of an embedded Site PI at each health system with expertise in local
data sources, and an understanding of the local clinical and operational context. A high level of trust among collaborators was also a

key ingredient to successful implementation. Each site made important
contributions to developing algorithms and in data interpretation—
data were not simply aggregated together. A distributed model is
employed because of the importance of local control and the preservation of data privacy, critical concerns of the health systems. The registry leverages existing and long-standing investments by the health
systems to build and sustain electronic health care data—it is not a
“plug and go” approach, but one that requires significant investment.

Limitations
The registry has limitations common to all observational studies relying on secondary data sources. Pharmacy fills may not capture actual
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Figure 2. Outpatient opioid fills and morphine milligram equivalents per member-month by month, all opioid registry sites combined, 2012–2018.
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Figure 5. Outpatient morphine milligram equivalents filled per member-month by race/ethnicity and month, all opioid registry sites combined, 2012–2018.

Table 4. Interrupted time series analysis of change in morphine milligram equivalents per member-month after 2016 revised CDC opioid
use guidelines, all registry sites combined
Morphine milligram equivalents per member per month
Interrupted time series model variable
Intercept
Preguideline expected trend
Postguideline shift
Postguideline change in trend
*Significant at P  .05.

Start year: 2012
60.44 (59.00, 61.89)*
0.33 (0.38, 0.29)*
0.72 (2.03, 0.59)
0.11 (0.19, 0.03)*

Start year: 2014
53.41 (52.66, 54.17)*
0.40 (0.45, 0.36)*
0.26 (1.03, 0.51)
0.04 (0.09, 0.02)
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Figure 4. Outpatient morphine milligram equivalents filled per member-month by age group and month, all opioid registry sites combined, 2012–2018.
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CONCLUSIONS AND FUTURE DIRECTIONS
Data from a multisite prescription opioid registry indicated a substantial reduction in opioid use over time due to both declines in the number of opioid prescriptions filled per member and in the MMEs per
fill. This registry and the infrastructure to create it could be leveraged
to respond to emerging knowledge gaps about the opioid crisis, such
as key questions about prescribing limits, deprescribing, use of opioids
for cancer, and the coronavirus disease 2019 pandemic impacts on
opioid prescribing; indeed some of these analyses are currently
planned as next steps. Although this infrastructure would require refreshing data over time and investments in data cleaning, local expertise, and scientific content knowledge to use effectively, it can be a
valuable resource both to generate hypotheses and test them using observational methods. To our knowledge, a similar multisite resource
using EHR data has not been described in the literature and we hope
the methods described are useful for other teams interested in developing a similar resource.
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